COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord

BMC Neurology

Volumn 6, Issue , 2006, Pages

  Yiangou, Yiangos ^a   Facer, Paul ^a   Durrenberger, Pascal ^a   Chessell, Iain P ^b   Naylor, Alan ^b   Bountra, Chas ^b   Banati, Richard R ^c   Anand, Praveen ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; FERRITIN; INTERLEUKIN 1BETA; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PURINE P2X7 RECEPTOR; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; ISOQUINOLINE DERIVATIVE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; P2RX7 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR; PURINERGIC P2X7 RECEPTOR;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BINDING SITE; CELL ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OPTICAL DENSITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SPINAL CORD DISEASE; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; CADAVER; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROTEIN BINDING; RADIOASSAY; SPINAL CORD;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BLOTTING, WESTERN; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOQUINOLINES; MACROPHAGES; MALE; MEMBRANE PROTEINS; MICROGLIA; MIDDLE AGED; MULTIPLE SCLEROSIS; POSTMORTEM CHANGES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB2; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2X7; SPINAL CORD;

EID: 33645224970     PISSN: 14712377     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-6-12     Document Type: Article

References (54)

1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994, 330(9):585-591.
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neural 1996, 39(3):285-294.
3. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999, 13(1):45-82.
4. Seffiert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P: Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol 1997, 400A: 167-170.
5. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK: Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997, 91(2):197-208.
6. Goppelt-Struebe M, Beiche F: Cyclooxygenase-2 in the spinal cord: localization and regulation after a peripheral inflammatory stimulus. Ady Exp Med Biol 1997, 433:213-216.
7. Sairanen T, Ristimaki A, Karjalainen-Lindsberg ML, Paetau A, Kaste M, Lindsberg PJ: Cyclooxygenase-2 is induced globally in infarcted human brain. Ann Neurol 1998, 43(6):738-747.
8. Willingale HL, Gardiner NJ, McLymont N, Giblett S, Grubb BD: Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol 1997, 122(8):1593-1604.
9. Badie B, Schartner JM, Hagar AR, Prabakaran S, Peebles TR, Bardey B, Lapsiwala S, Resnick DK, Vorpahl J: Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin Cancer Res 2003, 9(2):872-877.
10. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL: Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 2001, 57(6):952-956.
11. Almer G, Guegan C, Teismann P, Naini A, Rosoklija G, Hays AP, Chen C, Przedborski S: Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001, 49(2):176-185.
12. Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM: A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Faseb J 2003.
13. Klein TW, Newton C, Friedman H: Cannabinoid receptors and immunity. Immunol Today 1998, 19(8)373-381.
14. Kaminski NE: Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J Neuroimmunol 1998, 83(1-2):124-132.
15. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG:International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Phormacol Rev 2002, 54(2):161-202.
16. Mechoulam R. Spatz M, Shohami E: Endocannabinoids and neuro-protection. Sci STKE 2002, 2002(129):RES.
17. Coffey RG, Yamamoto Y, Snella E, Pross S: Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem Pharmacol 1996, 52(5):743-751.
18. Meda L, Cassatella MA, Szendrei G1, Otvos Lj, Baron P, Villalba M, Ferrari D, Rossi F: Activation of microglial cells by beta-amy-loid protein and interferon-gamma. Nature 1995, 374(6523):647-650.
19. Chung H, Brazil MI, Soe TT, Maxfield FR. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem 1999, 274(45)32301-32308.
20. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G: The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2×7). Science 1996, 272(5262):735-738.
21. Perregaux DG, Gabel CA: Human monocyte stimulus-coupled IL-1beta posttranslational processing. modulation via monovalent cations. Am J Physiol 1998, 275(6 Pt 1):C 1538-47.
22. Ferrari D, Chiozzi P, Faizoni S, Dall Susino M, Melchiorri L, Baricordi OR, Di Virgilio F: Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol 1997, 159(3):1451-1458.
23. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA: Altered cytokine production in mice lacking P2×(7) receptors. J Biol Chem 2001, 276(1):125-132.
24. Guan Z, Buckman SY, Miller BW, Springer LD, Morrison AR: Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. J Biol Chem 1998, 273(44):28670-28676.
25. Chakfe Y, Seguin R, Antel JP, Morissette C, Malo D, Henderson D, Seguela P: ADP and AMP induce interleukin-1beta release from microglial cells through activation of ATP-primed P2×7 receptor channels. J Neurosci 2002, 22(8)3061-3069.
26. Collo G, Neidhart S, Kawashirna E, Kosco-Vilbois M, North RA, Buell G: Tissue distribution of the P2×7 receptor. Neurophormacology 1997, 36(9):1277-1283.
27. Peudenier S, Hery C, Montagnier L, Tardieu M: Human microglial cells: characterization in cerebral tissue and in primary culture, and study of their susceptibility to HIV-1 infection. Ann Neurol 1991, 29(2):152-161.
28. Banati RB, Newcombe J, Gunn RN, Cagnin A. Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cumer ML, Myers R: The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. grain 2000, 123 (Pt II):2321-2337.
29. De Groot CJ,, Bergers E, Kamphorst W, Ravid R, Polman CH, Barkhof F, van der Valk P Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001, 124(Pt 8):1635-1645.
30. Nijeholt GJ, Bergers E, Kamphorst W, Bot J, Nicolay K, Castelijns JA, van Waesberghe JH, Ravid R, Polman CH, Barkhof F: Post-mortem high-resolution M111 of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. grain 2001, 124(Pt 1): 154-166.
31. Yiangou Y, Facer P, Baecker PA, Ford AP, Knowles CH, Chan CL, Williams NS, Anand R ATP-gated ion channel P2X(3) is increased in human inflammatory bowel disease. Neurogastroenterol Motil 2001, 13(4)365-369.
32. Banati RB, Myers R, Kreutzberg GW. PK (peripheral benzodiazepine') - binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 1997, 26(2):77-82.
33. Shah F, Hume SP, Pike VW, Ashworth S, McDermott J: Synthesis of the enantiomers of [N-methyl-11 C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol 1994, 21(4)573-581.
34. Maihofner C, Probst-Cousin S, Bergmann M, Neuhuber W, Neundorfer B, Heuss D: Expression and localization of cyclooxygenase 1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci 2003, 18(6):1527-1534.
35. Beiche F, Brune K, Geisslinger G, Goppelt-Struebe M: Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res 1998, 47(12):482-487.
36. Durrenberger PF, Facer P, Gray RA, Chessell IP, Nayfor A, Bountra C, Banati RB, Birch R, Anand P: Cyclooxygenase-2 (Cox-2) in injured human nerve and a rat model of nerve injury. J Peripher Nerv Syst 2004, 9(1):15-25.
37. Tonai T, Taketani Y, Ueda N, Nishisho T, Ohmoto Y, Sakata Y, Muraguchi M, Wada K, Yamamoto S: Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats. J Neurochem 1999, 72(1):302-309.
38. Resnick DK, Graham SH, Dixon CE, Marion DW: Role of cyclooxygenase 2 in acute spinal cord injury. J Neuratrauma 1998, 15(12):1005-1013.
39. Schipke CG, Boticsein C, Ohlemeyer C, Kirchhoff F, Kettenmann H: Astrocyte Ca2+ waves trigger responses in microglial cells in brain slices. Faseb J 2002, 16(2):255-257.
40. Ahmed SM, Rzigalinski BA, Willoughby KA, Sitterding HA, Ellis EF: Stretch-induced injury alters mitochondrial membrane potential and cellular ATP in cultured astrocytes and neurons. J Neurochem 2000, 74(5):1951-1960.
41. Verderio C, Matteoli M: ATP mediates calcium signalling between astrocytes and microglial cells: modulation by IFN-gamma. J Immunol 2001, 166(10):6383-6391.
42. Honda S, Kohsaka S: [Regulation of microglial cell function by ATP]. Nihon Shinkei Seishin Yakurigaku Zasshi 2001, 21(3):89-93.
43. Parvathenani LK Tertyshnikova S, Greco CR, Roberts SB, Robertson B, Posmantur R: P2×7 Mediates Superoxide Production in Primary Microglia and Is Up-regulated in a Transgenic Mouse Model of Aizheimer's Disease. J Biol Chem 2003, 278(15):13309-13317.
44. Choi HB, Khoo C, Ryu JK van Breemen E, Kim SU, McLarnon ]G: Inhibition of lipopolysaccharide-induced cyclooxygenase-2, tumor necrosis factor-alpha and [Ca2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195. J Neurochem 2002, 83(3):546-555.
45. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K Stelia N: Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003, 23(4):1398-1405.
46. Achiron A, Miron S, Lavie V, Margalit R, Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000, 102(1):26-31.
47. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404(6773):84-87.
48. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T: Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994, 28(3):209-214.
49. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D: Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003, 17(12):2750-2754.
50. Arevalo-Martin A Vela JM, Molina-Holgado E, Borrell J, Guaza C Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003, 23(7):2511-2516.
51. Croxford JIL, Miller SD: Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest 2003, 111(8):1231-1240.
52. Ibrahim MM, Deng 1-1, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TPJ: Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 2003, 100(18):10529-10533.
53. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cumer ML, Baker D: Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126(Pt 10):2191-2202.
54. Mallan TPJ, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 2003, 3(1):62-67.